Archive for Category: KD Research

Infliximab versus second IVIG for treatment of resistant KD in the USA (KIDCARE)

Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial Summary Background Although intravenous immunoglobulin (IVIG) is effective therapy for Kawasaki disease, 10–20% of patients have recrudescent fever...

Read More